Drugs / Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00544232 Background | Aug 2002 → Sep 2006 | breast cancer | GBG Forschungs GmbH | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00544232 ↗ |
| Route | Subcutaneous | “subcutaneous injection on day 2” NCT00544232 ↗ |